Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program Post published:January 18, 2022 Post category:Press Release
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients Post published:January 13, 2022 Post category:Press Release
Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds Post published:January 10, 2022 Post category:Press Release
Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services Post published:January 7, 2022 Post category:Press Release
Mydecine Signs LOI with Maya to Co-Develop a Novel Prescription Digital Therapeutic Platform Aiming to Further Increase Safety, Efficacy, and Accessibility of Psychedelic-Assisted Treatments Post published:December 22, 2021 Post category:Press Release
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives Post published:December 9, 2021 Post category:Press Release
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs Post published:December 6, 2021 Post category:Press Release
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021 Post published:November 10, 2021 Post category:Press Release
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients Post published:November 3, 2021 Post category:Press Release
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin Post published:October 27, 2021 Post category:Press Release